Pharma - Pharma Rep Focus

Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi

Fierce Pharma

NOVEMBER 4, 2024

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to launch its JAK inhibitor competitor to Eli Lilly and Incyte’s Olumiant and | Sun Pharma, which had been plotting a mid-October launch for its JAK inhibitor Leqselvi, has been slapped with in an injunction blocking the rollout of (..)

Pharma

After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe

Fierce Pharma

DECEMBER 2, 2024

After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe. | In turn, Intercept's liver disease drug, which is marketed by Advanz Pharma overseas, has lost its EU approval.

Marketing

Marketing Pharma

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

MedCity News

NOVEMBER 6, 2024

The post Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M appeared first on MedCity News. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome.

FDA

FDA Pharma Pharmaceutical Biopharma

Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute

Fierce Pharma

NOVEMBER 8, 2024

Sun Pharma's JAK inhibitor Leqselvi was slapped with an injunction in a lawsuit with Incyte. AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and improper collection of patient data. AstraZeneca confirmed its China president has been detained by Chinese authorities.

Pharma

Pharma Patients

Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

MedCity News

FEBRUARY 7, 2025

Bain Capitals buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. Deal for Mitsubishi Tanabe Pharma appeared first on MedCity News. The post Bain Capital Broadens Its Biotech Reach With $3.3B

Pharma

Pharma Pharmaceutical Biopharma

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

MedCity News

JUNE 13, 2025

The post AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact appeared first on MedCity News. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.

Pharma

Pharma Pharmaceutical Medical Biopharma

Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs

Fierce Pharma

NOVEMBER 5, 2024

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million deal with Royalty Pharma.

Pharma

Pharma FDA Pharmaceutical

From Public to Private: Do Laid-Off FDA and CDC Employees Have the Skills Pharma and Biotech Need?

World of DTC Marketing

JUNE 6, 2025

While these individuals bring a wealth of scientific expertise, policy knowledge, and regulatory acumen, thriving in the commercial world of pharma and biotech often requires a mindset shift—and sometimes, a skills upgrade. The short answer is yes, but with caveats. What Laid-Off Government Employees Bring to the Table 1.

Pharma

Pharma FDA Ethics Government

It’s Time to Admit: In an Era of High Distrust, Pharma DTC TV Ads Are Ineffective

World of DTC Marketing

JUNE 9, 2025

For decades, pharma companies have relied on direct-to-consumer (DTC) television ads to build awareness and drive demand for prescription drugs. Awareness Alone Isn’t Enough Pharma DTC ads still do one thing reasonably well: generate broad awareness. A 60-second ad spot during prime time or sports broadcasts ensures mass reach.

Pharma

Pharma Doctors Physicians Prescription

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway

MedCity News

APRIL 7, 2025

The post Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway appeared first on MedCity News. The engineered peptide drug is already approved for two genetically driven types of obesity.

Pharma

Pharma Engineering Pharmaceutical FDA

Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels

MedCity News

MARCH 23, 2025

The post Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels appeared first on MedCity News. But Apellis Pharmaceuticals Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy.

FDA

FDA Pharma Pharmaceutical Biopharma

The Challenges Of HCPs Accessing Reliable Online Medicines Information and What Pharma Companies Can Do To Improve Information Sharing

MedCity News

MARCH 27, 2025

The post The Challenges Of HCPs Accessing Reliable Online Medicines Informationand What Pharma Companies Can Do To Improve Information Sharing appeared first on MedCity News.

Medicine

Medicine Pharma Biopharma

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s

MedCity News

MARCH 28, 2025

The post Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s appeared first on MedCity News. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisks Wegovy.

Pharma

Pharma Pharmaceutical Biopharma

'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says

Fierce Pharma

NOVEMBER 1, 2024

said in an interview with Fierce Pharma. Now, less than a year later, the FDA is reconsidering those serious safety warnings with plans to potentially change them, CBER Director Peter Marks, M.D.,

FDA

FDA Safety Pharma Patients

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

MedCity News

NOVEMBER 25, 2024

BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.

Competition

Competition FDA Pharma Pharmaceutical

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

MedCity News

JANUARY 12, 2025

Gilead Sciences is acquiring LEO Pharmas oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference.

Pharma

Pharma Healthcare Healthcare Biopharma

Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More

MedCity News

JANUARY 23, 2025

Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said.

Pharma

Pharma Medical Biopharma

Sanofi charts biggest China investment to date with plans for €1B insulin 'manufacturing base' in Beijing

Fierce Pharma

DECEMBER 2, 2024

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date. Sanofi is laying out roughly 1 billion euros ($1.04

Manufacturing

Manufacturing Pharma

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

MedCity News

JANUARY 31, 2025

The post Vertex Pharmas Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds appeared first on MedCity News. Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain.

FDA

FDA Medicine Pharma Pharmaceutical

Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide

Fierce Pharma

OCTOBER 23, 2024

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and (..)

FDA

FDA Manufacturing Pharma

AbbVie’s ADC win shows how pharma can break through in solid tumors

PharmaVoice

MAY 30, 2025

An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

Pharma

Pharma Leads

Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs

MedCity News

NOVEMBER 4, 2024

This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity.

Pharma

Pharma FDA Leads Biopharma

AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition

MedCity News

MARCH 17, 2025

AstraZenecas EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases. EsoBiotecs allogeneic cell therapies are made by the in vivo reprogramming of a patients immune cells.

Pharma

Pharma Patients Biopharma

Fast-growing Adragos snaps up Swiss CDMO Baccinex, significantly expanding fill-finish firepower

Fierce Pharma

NOVEMBER 26, 2024

German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a facility in France, taking over another from Fresenius Kabi in Norway and more | German CDMO Adragos Pharma has been on a growth tear this year.

Specialization

Specialization Networking Pharma Manufacturing

Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella

Fierce Pharma

OCTOBER 11, 2024

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private equity outfit Clayton, Dubilier & Rice to potentially sell a 50% controlling stake in its consumer health business, Opella.

Pharma

Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet

Fierce Pharma

OCTOBER 23, 2024

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court.

Pharma

Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda

MedCity News

NOVEMBER 19, 2024

Merck said topline Phase 3 results show an injectable version of Keytruda met the main goal of non-inferiority compared to the intravenously infused formulation that is the pharma giant’s top-selling product. Injectable Keytruda could help Merck compete against coming competition from biosimilars.

Competition

Competition Pharma Biopharma

Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity

MedCity News

MARCH 12, 2025

Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.

Pharma

Pharma Biopharma

Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications

MedCity News

OCTOBER 28, 2024

The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer. Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders.

Pharma

Pharma Biopharma

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

MedCity News

JUNE 11, 2025

It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. billion acquisition of RayzeBio last year.

Pharma

Pharma Biopharma

Fierce Pharma - Untitled Article

Fierce Pharma

JUNE 6, 2025

How data-driven partnerships and precision engagement are redefining pharma's role in patient care

Pharma

Pharma Patients

Is pharma ready to let go of animal testing?

PharmaVoice

MAY 2, 2025

Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.

Pharma

Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site

MedCity News

DECEMBER 16, 2024

Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications. Novo Nordisks new Denmark site will produce drugs for rare diseases, such as hemophilias.

Manufacturing

Manufacturing Pharma Medical Biopharma

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World

MedCity News

JANUARY 24, 2025

Ascentage Pharmas U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S.

Pharma

Pharma Leads Biopharma

At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor

MedCity News

JUNE 1, 2025

Merck KGaAs pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma.

Pharma

Pharma Medical Biopharma

Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases

MedCity News

MARCH 24, 2025

Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies. Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon.

Pharma

Pharma Medical Biopharma

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

MedCity News

MAY 16, 2025

Inozyme Pharmas main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications.

Pharma

Pharma Pharmaceutical Marketing Biopharma

Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers

Fierce Pharma

OCTOBER 23, 2024

Now, a new complaint has surfaced—not from lawmakers or consumer groups but a major pharma CEO. While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks.

Pharma

Fierce Pharma - Untitled Article

Fierce Pharma

JUNE 6, 2025

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.

Pharma

Pharma Marketing

Fierce Pharma - Untitled Article

Fierce Pharma

JUNE 11, 2025

is going toe to toe with the New York drugmaker and two other pharma giants in a lung cancer field. Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D.,

Pharma

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

PharmaVoice

MAY 21, 2025

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

Pharma

What Happened to Pharma’s DTC Visionaries? Understanding Today’s Dull Ads

World of DTC Marketing

JUNE 8, 2025

Direct-to-consumer (DTC) pharma marketing once burst onto the scene with bold creativity, powerful storytelling, and game-changing blockbuster drugs. So, what happened to those visionary marketers, and why has pharma advertising become so bland? Pharma DTC advertising doesn’t have to be boring. The 2010s marked a distinct shift.

Pharma

Pharma Marketing Side effects Physicians

Fierce Pharma - Untitled Article

Fierce Pharma

JUNE 6, 2025

DeepIntent’s Jay Richetelli discusses the role of AI, data ownership and trust in shaping the next era of pharma marketing

Pharma

Pharma Marketing

With TV ads under threat, here’s how pharma can leverage social media

PharmaVoice

MAY 7, 2025

’s plan to ban TV advertising may shift more marketing attention to online platforms.

Media

Media Pharma Marketing

Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi

After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe

Trending Sources

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute

Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma

AstraZeneca Turns to CSPC Pharma Again, Putting Up $110M to Start Multi-Drug R&D Pact

Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs

From Public to Private: Do Laid-Off FDA and CDC Employees Have the Skills Pharma and Biotech Need?

It’s Time to Admit: In an Era of High Distrust, Pharma DTC TV Ads Are Ineffective

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway

Novartis Nabs First FDA Nod in Rare Kidney Disease, But Apellis Pharma Is on Its Heels

The Challenges Of HCPs Accessing Reliable Online Medicines Information and What Pharma Companies Can Do To Improve Information Sharing

Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s

'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More

Sanofi charts biggest China investment to date with plans for €1B insulin 'manufacturing base' in Beijing

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide

AbbVie’s ADC win shows how pharma can break through in solid tumors

Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs

AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition

Fast-growing Adragos snaps up Swiss CDMO Baccinex, significantly expanding fill-finish firepower

Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella

Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet

Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda

Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity

Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Fierce Pharma - Untitled Article

Is pharma ready to let go of animal testing?

Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site

Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World

At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor

Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases

BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers

Fierce Pharma - Untitled Article

Fierce Pharma - Untitled Article

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

What Happened to Pharma’s DTC Visionaries? Understanding Today’s Dull Ads

Fierce Pharma - Untitled Article

With TV ads under threat, here’s how pharma can leverage social media

Stay Connected